Photocure ASA (OSL:PHO)

Market Cap	1.16B -26.0%
Revenue (ttm)	684.69M +27.4%
Net Income	48.55M +2,192.1%
EPS	1.81 +2,251.3%
Shares Out	26.97M
PE Ratio	23.63
Forward PE	38.26
Dividend	n/a
Ex-Dividend Date	n/a

Volume	75,709
Open	41.50
Previous Close	41.90
Day's Range	41.50 - 43.20
52-Week Range	41.50 - 79.80
Beta	0.23
Analysts	Strong Buy
Price Target	75.00 (+75.03%)
Earnings Date	Oct 28, 2026

About Photocure ASA

Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through two segments, Commercial Franchise and Development Portfolio. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Cevira, a photodynamic drug-device combination product candidate for the non-surgical treatment of high-grade cervical dysplasia. The company has a license agreement with Asieris MediTech Co to develop...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 101
• Stock Exchange: Oslo Børs
• Ticker Symbol: PHO

Financial Performance

In 2025, Photocure ASA's revenue was 532.58 million, an increase of 1.37% compared to the previous year's 525.39 million. Losses were -1.52 million, -54.58% less than in 2024.

Analyst Summary

According to 3 analysts, the average rating for PHO stock is "Strong Buy." The 12-month stock price target is kr 75.00, which is an increase of 75.03% from the latest price.

Price Target

kr 75.00

(75.03% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 13, 2026

Data Sources Report a data error